683 related articles for article (PubMed ID: 18929351)
1. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Tabbara KF; Al-Hemidan AI
Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease.
Bae JH; Lee SC
Retina; 2012 Jul; 32(7):1395-402. PubMed ID: 22012204
[TBL] [Abstract][Full Text] [Related]
4. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Kawaguchi T; Mochizuki M
Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
6. Retrospective case review of pediatric patients with uveitis treated with infliximab.
Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
[TBL] [Abstract][Full Text] [Related]
8. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
9. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E
Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187
[TBL] [Abstract][Full Text] [Related]
10. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
11. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
[TBL] [Abstract][Full Text] [Related]
14. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R
Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
Kalb RE; Gurske J
J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease.
Capella MJ; Foster CS
Ocul Immunol Inflamm; 2012 Jun; 20(3):198-202. PubMed ID: 22486265
[TBL] [Abstract][Full Text] [Related]
18. Infliximab in the treatment of refractory posterior uveitis.
Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
[TBL] [Abstract][Full Text] [Related]
19. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
Navarro FA; Hanauer SB; Kirschner BS
J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):312-8. PubMed ID: 17873743
[TBL] [Abstract][Full Text] [Related]
20. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.
Markomichelakis N; Delicha E; Masselos S; Fragiadaki K; Kaklamanis P; Sfikakis PP
Rheumatology (Oxford); 2011 Mar; 50(3):593-7. PubMed ID: 21097877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]